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and neurobiology of schizophrenia have not been fully established and 
validated in this species. MK-801, an NMDA receptor antagonist, is fre-
quently used to recapitulate schizophrenia symptoms in rodent models. We 
thus aimed to evaluate the effects of a concentration curve of MK-801 on 
locomotor activity, social interaction, and neurochemical parameters re-
lated to oxidative stress in adult zebrafish.
Methods: Wild-type male and female zebrafish (50:50 ratio) were randomly 
allocated to 4 groups: control; 1 µM MK-801; 5 µM MK-801 or 10 µM 
MK-801 (n = 12). In the locomotor activity test animals were individually 
and sequentially placed in (1) a beaker with 200 mL of water for 20 min, 
(2) test aquarium for 30 min to assess basal locomotor activity, (3) beaker 
with water or MK-801 at the different concentrations for 20 min, and (4) 
test aquarium for 60 min. Locomotor and exploratory parameters (total 
distance traveled and upper zone time) were automatically analyzed using 
ANY-Maze software. In the social interaction test animals were individu-
ally exposed to water or MK-801 for 20 min and then placed for 7 min in a 
tank flanked by two identical tanks either empty or containing 10 zebrafish 
serving as social stimuli. Distance traveled was automatically tracked 
while social interaction time was manually and blindly scored using Boris 
software; only the last 5 minutes were analyzed. Oxidative damage in the 
brain was assessed by the levels of thiobarbituric acid reactive substances 
(TBARS). Data were analyzed by ANOVA followed by Tukey post hoc test.
Results: Exposure to 5 µM MK-801 decreased the total distance traveled 
in the locomotor activity test. In the social interaction test, exposure to 
5 and 10  µM MK-801 significantly increased the total distance traveled 
while reduced the time of social interaction with the stimulus animals. No 
differences in TBARS levels were found between the groups.
Discussion: Unlike what is observed in rodents after MK-801 adminis-
tration, zebrafish did not show hyperlocomotion at the concentrations 
tested. Other studies point to the context-dependent effect of  this drug, as 
an increase in locomotor activity is only observed when animals are tested 
in a novel environment. In the social interaction test, on the other hand, 
animals were tested in a novel context with social stimulus and zebrafish 
exhibited hyperlocomotion and decreased social interaction, similar to 
what is observed in rodents. In contrast to chronic animal models and 
patients with schizophrenia, there were no differences in TBARS levels 
after acute exposure to MK-801. These preliminary results reinforce that 
zebrafish is an alternative model organism useful to the study of  psychotic 
disorders. More behavioral and biochemical tests are needed to achieve 
reproducible tests and models to study multiple schizophrenia domains 
in zebrafish.
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Background: Evidence from clinical and preclinical studies has led to 
the hypothesis that impaired glutamatergic transmission and NMDA 
receptor hypofunction play an important role in cognitive impairment 
associated with schizophrenia (CIAS). Second messenger pathways 
depending on cAMP and/or cGMP are key regulators of  glutamatergic 
transmission and NMDA receptor related pathways. Therefore, the spe-
cific cyclic nucleotide phosphodiesterases (PDEs) PDE2 and PDE9, 
expressed in cognition relevant brain regions such as cortex and hip-
pocampus, are putative targets for cognition enhancement in neuropsy-
chiatric disorders (Dorner-Ciossek et al., 2017; Zhang et al., 2017). In 
fact, it has previously been shown that either PDE2 or PDE9 inhibition 
increases synaptic plasticity, as determined by hippocampal long-term 
potentiation (LTP), and improves memory performance in animal cog-
nition tasks. However, the exact sub-cellular localization of  PDE2 and 
PDE9 enzymes in neurons is not fully established. Thus, in the present 
study, co-localization studies of  PDE2 and PDE9 with pre- and post-
synaptic markers were performed by double immunofluorescence 
staining. Moreover, the PDE2 inhibitor PF-05180999 (Helal et  al., 
2018)  was characterized regarding enhancement of  hippocampal LTP 
and further investigated in combination with the PDE9 inhibitor Bay 
73–6691 (Wunder et al., 2005) for potential synergistic effects on LTP.
Methods: Brains of adult rats were fixed with formalin and sliced for double 
immunofluorescence staining of PDE2 or PDE9 enzymes with pre-/post-
synaptic markers. Analysis of staining was performed by confocal micros-
copy. Effects of the PDE2 inhibitor PF-05180999 alone and in combination 
with the PDE9 inhibitor Bay 73–6691 on synaptic plasticity were evaluated 
in rat hippocampal slices by using a protein-synthesis independent early 
LTP paradigm.
Results: Double immunofluorescence analysis revealed co-localization of 
PDE2 predominantly with pre-synaptic, but not post-synaptic, markers and 
mainly in glutamatergic neurons. In contrast, PDE9 showed co-localization 
with post-synaptic markers. Inhibition of PDE2 by PF-05180999 led to 
a concentration-dependent enhancement of early LTP. Combination of 
PF-05180999 with a subthreshold concentration of the PDE9 inhibitor Bay 
73–6691 caused a transformation from early LTP into protein-synthesis de-
pendent late LTP.
Discussion: Immunofluorescence staining suggests that PDE2 is localized 
pre-synaptically in glutamatergic neurons. This might indicate an involve-
ment of PDE2 in neurotransmitter release via regulating cGMP/cAMP 
levels at pre-synaptic terminals, whereas PDE9 is located post-synaptically 
presumably involved in the NMDA receptor signaling cascade via regula-
tion of cGMP. Corroborating previous findings, PDE2 inhibition improves 
synaptic plasticity as shown by enhanced LTP. Moreover, for the first time, 
we could show that the combination of a PDE2 with a PDE9 inhibitor acts 
synergistically on improvement of synaptic plasticity as demonstrated by 
the shift from early into late LTP, which is considered to be a crucial mech-
anism for memory formation.
References 
Dorner-Ciossek et al. (2017), Adv. Neurobiol. 17, 231–254.
Helal et al. (2018), J. Med. Chem. 61, 1001–1018.
Wunder et al. (2005), Mol.Pharmacol. 68, 1775–1781.
Zhang et al. (2017), Adv. Neurobiol. 17, 307–347.
S32. ARE SELECTIVE ESTROGEN RECEPTOR 
BETA AGONISTS POTENTIAL THERAPEUTICS 
FOR SCHIZOPHRENIA?
Alan Breier*1, Emily Liffick2, Tom Hummer2, Jennifer Vohs2, 
Nicole Mehdiyoun2, Ziyi Yang2, Andrew J Saykin3,  
Brenna McDonald3, Michael Francis2
1Indiana Univ School of Medicine; 2Indiana University School of 
Medicine; 3Indiana University School of Medicine
Background: Estrogen therapies, such as estradiol, have shown promise as 
therapeutics for schizophrenia; however, safety and tolerability concerns, 
including feminization effects in men and cancer and stroke risk in pre-
menopausal women, may limit their broader use. Estradiol binds to both 
the estrogen alpha (ERA) and beta (ERB) receptors. ERB receptors appear 
not to mediate many of the concerning side effects of estrogen therapies. 
In addition, beta receptors have unique localization in cortical regions (i.e., 
hippocampus), and improve social behaviors and cognition in some animal 
models, which has led to interests in these compounds for testing in schizo-
phrenia. To our knowledge, there have been no previous clinical trials of se-
lective ERB agonists in schizophrenia. LY500307 is a highly selective agent 
SIRS 2020 Abstracts
S44 Poster Session I 
for beta receptors without effects on estrogen alpha receptors when doses 
are constrained. Doses that are too high may engage alpha receptors but 
the alpha engaging threshold dose has not been fully determined in pa-
tient groups. The purpose of this dose-response study was to determine: 
ERB selectivity doses of LY500307 (i.e., without engaging alpha receptors); 
safety and tolerability; brain target engagement; and effects on cognition 
and symptoms.
Methods: A two-staged, double-blind, 8-week, adjunctive to APDs, 
adaptive phase 1b/2a trial design was conducted in men with schizophrenia 
(women were not included because of the lack of toxicology, safety, phase 1 
and clinical data supporting use in this population). Three LY500307 doses 
and placebo were evaluated: 25 mg/day, 75 mg/day, and 150 mg/day. The 
primary markers for estrogen beta receptor selectivity was lack of effects on 
total testosterone levels (TT) and no feminization signs. Target engagement 
was assessed with an N-back working memory fMRI task and the electro-
physiology measure mismatch negativity (MMN). Cognitive effects were 
assessed by the MCCB Composite score. Negative and total symptoms were 
assessed by the NSA-16 and PANSS, respectively. The primary analyses in-
cluded all subjects and compared the slope from the three LY500307 dosing 
arms to the placebo slope in order to evaluate the dose responses. The linear 
mixed model with random intercept was employed and secondary analyses 
assessed differences between mean changes of the two higher dose arms 
combined (75 mg and 150 mg) versus placebo.
Results: Ninety-four patients were randomized across the placebo and 
three LY500307 dosing arms. There were no effects on plasma TT levels 
and no evidence of feminization, suggesting all doses were selective for the 
beta receptor. No significant adverse events were observed. There were no 
significant differences between the slopes of the three drug doses versus 
placebo on the brain target engagement variables (fMRI/N-back: F=0.24, 
p=0.868; MMN (Duration): F=1.08, p=0.358; MMN (Frequency): F=0.89, 
p=0.446) or on the cognitive/symptom measures (MCCB composite: 
F=0.87, p=0.458; NSA-16: F=1.79, p=0.148; and PANSS Total: F=0.69, 
p=0.558.) Secondary analyses also failed to show any significant effects of 
LY500307 versus placebo on any of the study variables.
Discussion: Conclusions: This study indicates that the ERB agonist 
LY500307 was selective, safe, and well tolerated in patients with schizo-
phrenia. This selective ERB agonist, however, failed to demonstrate any 
significant effects on brain targets, cognition, negative and total symptoms. 
Potential issues related to dosing and characteristics of the patient popula-
tion will be discussed. These data suggest that estrogen alpha receptor acti-
vation may be necessary to yield positive results in this patient population. 
Future studies are needed to confirm these findings.
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Background: Relatives often provide extensive support to their next of kin 
suffering from psychotic disorders. However, they often experience lack 
of support from psychiatric services. While cooperation with relatives is 
a central component in Resource Group Assertive Community Treatment 
(RACT), little is known about relatives’ experiences of RACT. The aim was 
to investigate relatives’ experiences of encountering psychiatric care with 
and without RACT, in relation to quality of life, family burden and family 
stigma.
Methods: A total of 139 relatives of individuals suffering from psychotic 
disorders in the Region Västra Götaland, Sweden filled out the self-report 
instruments Family Involvement and Alienation Questionnaire – Revised 
(FIAQ-R), the Burden Inventory for Relatives of Persons with Psychotic 
Disturbances, the Inventory of Stigmatizing Experiences (family version), 
and RAND-36.
Results: Participants included 79 relatives with experience of RACT and 60 
without. In the total group 70% were women. Mean age was 63 years (SD 
12.4). A majority came from Sweden (91%), had >12 years of education (61%) 
and did not live together with the patient (76%). A  majority were parents, 
(70%). These demographic characteristics did not differ in those with and 
without RACT. We found that relatives who participated RACT experienced 
a more positive approach from the healthcare professionals compared to those 
without RACT (p=.001). Furthermore, relatives who participated in RACT 
felt to a lower extent that they were alienated from the provision of care than 
did other relatives (p=.005). Relatives who did not participate in resource group 
were significantly more afraid that their ill next of kin would hurt someone. 
The association remained after adjustment for experience of approach and 
feeling of alienation. No other differences in family burden variables were 
found. Findings regarding mental Quality of Life scores and experiences of 
family stigmatization were similar in those both with and without RACT.
Discussion: The results suggest that participating in RACT may contribute 
to a higher level of satisfaction for relatives in their encounter with health-
care professionals.
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Background: The individual Metacognitive Training (MCT+) is useful to re-
duce positive symptoms in people with schizophrenia, however less is known 
in people with first-episode psychosis (FEP). The aim of the study is to assess 
the effectiveness of MCT+ in FEP regarding symptoms and cognitive insight.
Methods: A random clinical trial was performed with people with FEP 
from 10 clinical centers of Spain. One group received ten sessions of MCT+ 
and the other group received TAU. A  total of 75 patients were included 
in the study, however only 40 finished the final assessment. Patients were 
assessed before treatment, post-treatment and 6 month follow-up. The as-
sessment includes a battery of instruments for the main aims the Positive 
and Negative Syndrome Scale (PANSS) and the Beck Cognitive Insight 
(BCIS) will be analyzed. Repeated measures statistical test were used in 
order to assess differences between groups.
